Author Topic: (Abst.) Risk of SPMS: A longitudinal study  (Read 42 times)

0 Members and 0 Guests are viewing this topic.

Offline agate

  • Administrator
  • *****
  • Posts: 8558
  • MS diagnosed 1980
  • Location: Pacific Northwest
(Abst.) Risk of SPMS: A longitudinal study
« on: August 11, 2019, 03:07:56 pm »

From PubMed (August 10, 2019)--"Risk of secondary progressive multiple sclerosis: A longitudinal study":

https://www.ncbi.nlm.nih.gov/pubmed/31397221


Though this study doesn't seem to be saying anything especially new, the last sentence in the abstract:


Quote
Therapy [with MS drugs] may delay the onset of secondary progression.


In the past there have been claims that therapy with MS drugs do delay the onset of secondary progression. This article states only that it "may delay" SPMS onset.



MS Speaks--online for 13 years

SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010.

Offline agate

  • Administrator
  • *****
  • Posts: 8558
  • MS diagnosed 1980
  • Location: Pacific Northwest
An editorial about this study--from Multiple Sclerosis Journal (August 12, 2019), "Big data in MS: What can we learn from large international observational studies such as MSBase?":


https://journals.sagepub.com/doi/full/10.1177/1352458519868982
MS Speaks--online for 13 years

SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010.

 

Related Topics

  Subject / Started by Replies Last post
4 Replies
117 Views
Last post April 11, 2017, 07:11:54 pm
by agate
0 Replies
63 Views
Last post November 16, 2016, 08:37:33 am
by agate
1 Replies
103 Views
Last post November 14, 2018, 04:04:14 pm
by agate
0 Replies
47 Views
Last post April 01, 2018, 01:43:26 pm
by agate
0 Replies
30 Views
Last post August 01, 2019, 07:27:51 am
by agate